CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 0.95×, higher than 95% of its Biotechnology peers (median 0.09×)
- FinancialsAltman Z-Score 2.67: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
2.83BCNY420.42M · vs all stocks (USD)
Trailing P/E
67.62xvs Biotechnology peers
Revenue (TTM)
512.79MCNY76.05M · vs all stocks (USD)
Profit Margin
8.22%vs Biotechnology peers
Beta
0.3870xvs all stocks
52-Week Change
-16.11%vs all stocks
Market Capitalization
2.83BCNY420.42M · vs all stocks (USD)
Enterprise Value
3.04BCNY450.75M · vs all stocks (USD)
Trailing P/E
67.62xvs Biotechnology peers
Price to Sales (TTM)
5.66xvs Biotechnology peers
Price to Book (MRQ)
10.48xvs Biotechnology peers
Enterprise to Revenue
5.93xvs Biotechnology peers
Enterprise to EBITDA
96.64xvs Biotechnology peers
Gross Margin
20.46%vs Biotechnology peers
Profit Margin
8.22%vs Biotechnology peers
Operating Margin
10.85%vs Biotechnology peers
Return on Assets (TTM)
2.04%vs Biotechnology peers
Return on Equity (TTM)
11.07%vs Biotechnology peers
Revenue (TTM)
512.79MCNY76.05M · vs all stocks (USD)
Revenue per Share (TTM)
1.60CNYUpdated Aug 18, 2026Quarterly Revenue Growth
431.30%vs Biotechnology peers
Gross Profit (TTM)
101.00MCNY14.98M · vs all stocks (USD)
EBITDA (TTM)
46.12MCNY6.84M · vs all stocks (USD)
Net Income (TTM)
42.15MCNY6.25M · vs all stocks (USD)
Operating Cash Flow (TTM)
-205.61MCNY-30.49M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-247.93MCNY-36.77M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
91.76MCNYFY2025 · Dec 31, 2025Revenue
415.94MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
324.14MCNYFY2025 · Dec 31, 2025Gross Profit
91.80MCNYFY2025 · Dec 31, 2025Operating Income
30.86MCNY4.58M · vs all stocks (USD)
Pre-tax Income
19.72MCNYFY2025 · Dec 31, 2025Income Tax Expense
1.67MCNYFY2025 · Dec 31, 2025Net Income
18.05MCNYFY2025 · Dec 31, 2025EBIT
21.72MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
46.12MCNYFY2025 · Dec 31, 2025Research & Development
7.66MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
19.37MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.82MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.13MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.00MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0900CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
320.32MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
320.32MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
18.05MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
10.78MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-127.42MCNYFY2025 · Dec 31, 2025Free Cash Flow
-132.52MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
346.77MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
18.05MCNYFY2025 · Dec 31, 2025Other Non-cash Items
26.53MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-173.67MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.67MCNYFY2025 · Dec 31, 2025Capital Expenditures
-5.10MCNYFY2025 · Dec 31, 2025Net Acquisitions
-61.23MCNYFY2025 · Dec 31, 2025Purchase of Investments
-178.00MCNYFY2025 · Dec 31, 2025Sale of Investments
282.08MCNYFY2025 · Dec 31, 2025Other Investing Activity
-10.86MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
26.89MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
22.30MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-33.52MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-2.37MCNYFY2025 · Dec 31, 2025Other Financing Charges
243.42MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
229.84MCNYFY2025 · Dec 31, 2025Shares Outstanding
330.02MSharesUpdated Aug 18, 2026Float Shares
222.32MSharesUpdated Aug 18, 2026% Held by Insiders
8.61%vs all stocks
% Held by Institutions
40.53%vs all stocks
Total Cash (MRQ)
303.38MCNY44.99M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.9190CNYUpdated Aug 18, 2026Total Debt (MRQ)
349.68MCNY51.86M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.9475xvs Biotechnology peers
Current Ratio (MRQ)
1.38xvs Biotechnology peers
Book Value per Share (MRQ)
0.8390CNYUpdated Aug 18, 2026Total Assets
991.73MCNY147.07M · vs all stocks (USD)
Total Current Assets
738.92MCNYFY2025 · Dec 31, 2025Total Liabilities
634.22MCNYFY2025 · Dec 31, 2025Total Non-current Assets
252.81MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
89.07MCNYFY2025 · Dec 31, 2025Total Current Liabilities
545.16MCNYFY2025 · Dec 31, 2025Cash
346.04MCNYFY2025 · Dec 31, 2025Cash Equivalents
723.81KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
346.77MCNYFY2025 · Dec 31, 2025Accounts Receivable
218.52MCNYFY2025 · Dec 31, 2025Inventory
18.67MCNYFY2025 · Dec 31, 2025Accounts Payable
14.72MCNYFY2025 · Dec 31, 2025Short-term Debt
285.06MCNYFY2025 · Dec 31, 2025Other Current Liabilities
12.33MCNYFY2025 · Dec 31, 2025Long-term Debt
56.19MCNYFY2025 · Dec 31, 2025Common Stock (Book)
330.02MCNYFY2025 · Dec 31, 2025Retained Earnings
-522.12MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
357.51MCNY53.02M · vs all stocks (USD)
52-Week Low
7.02CNYUpdated Aug 18, 202652-Week High
10.81CNYUpdated Aug 18, 202652-Week Change
-16.11%vs all stocks
Beta
0.3870xvs all stocks
50-Day MA
8.06CNYUpdated Aug 18, 2026200-Day MA
8.98CNYUpdated Aug 18, 2026Avg 10-Day Volume
8.78MSharesUpdated Aug 18, 2026Avg 30-Day Volume
9.67MSharesUpdated Aug 18, 2026Diluted EPS (TTM)
0.1300CNYUpdated Aug 18, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Working Capital Pattern
What customers owe has grown three years running, while it clears stock quickly and pays suppliers quickly.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0.95×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 0.95Industry median: 0.09Industry P95: 0.88Peers compared: 261
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 4.31Receivables vs revenue divergence: 2.77
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 6,250,548.993Operating Cash Flow (USD, TTM): -30,492,240.618
Financial Health
Altman Z-Score 2.67: safe zoneNotable
Altman Z-Score: 2.67
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Tenax Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Elite Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abclon Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Kehua Bio-Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hua Medicine Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Novartis India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangsu Canopus Wisdom MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Jiaoda Onlly Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Qinghai Spring Medicinal Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Grinm Advanced Materials Co., Ltd.
1 interpretationWorking Capital Pattern
C-MER Medical Holdings Ltd.
1 interpretationWorking Capital Pattern
Chipotle Mexican Grill, Inc.
1 interpretationWorking Capital Pattern